Vantage Hemp

What Vantage Hemp does

Vantage Hemp Co. is a privately held, pharmaceutical-grade cannabinoid Active Pharmaceutical Ingredient (API) manufacturer founded in December 2018 and headquartered in Greeley, Colorado. The company operates two custom-built cGMP-certified facilities (Falcon and Raven) totaling 62,000 sq ft of certified hemp processing, with annual production capacity of 100,000 kg of CBD distillate, 50,000 kg of CBD isolate, and more than 50 million softgel capsules and 1 million tinctures. Its core technology stack combines CO2 and hydrocarbon extraction, winterization, dual-stage distillation using Chemtech KD30 systems, and crystallization, yielding APIs that comply with FDA Drug Master Files (#036876 distillate; #037784 isolate), ICH Q7, WHO GMP, FDA 21 CFR 210/211, TGA PIC/S, and European Pharmacopoeia monographs.

The company's revenue model spans four streams: B2B contract manufacturing of bulk CBD distillate and isolate, white-label and private-label production of finished softgel and tincture formats, R&D and clinical trial supply, and exclusive regional distribution partnerships (WELDING GmbH in Europe/India/North Macedonia; Medcan Australia in Australia; a Brazilian partner for ANVISA market access). Customer segmentation is vertical, prioritizing pharmaceutical companies requiring regulatory-grade APIs, followed by nutraceutical, cosmetics, and food-additive manufacturers, plus CBD brand owners seeking outsourced manufacturing. The CMS Substance Access Beneficiary Engagement Incentive (Medicare CBD Pilot) introduced in 2026 represents an emerging go-to-market vector into U.S. value-based care through ACOs and GPOs.

The company is founder- and operator-owned with no disclosed external investors, and is led by CEO Rusty Kuchta (RPh), COO Deepank Utkhede (20+ years pharmaceutical manufacturing), CSO Dr. Daniel Chinnapen (former Harvard Medical School professor), CMO Dr. Paul Shields (DO), and CRO Harvinder Johal. Operational leadership is anchored by Director of Regulatory Affairs and Quality Assurance Laura Eder and Director of Sales Christian Santi, with an 11–50 employee headcount concentrated in Greeley.

Name

Vantage Hemp

Legal name

Vantage Hemp Co.

Website

https://vantagehemp.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Vantage Hemp is a privately held, cGMP-certified manufacturer of pharmaceutical-grade CBD and CBG active pharmaceutical ingredients and finished products (softgels, tinctures), selling bulk APIs and white-label services to pharmaceutical, nutraceutical, cosmetics, and food companies globally.

Ownership category

akta.pro rank

Product category

Pharmaceutical Cannabinoid API Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Controlled Substances / DEA-Scheduled API Manufacturing (HLAGAHAD)

akta.pro secondary industries

Herbal & Botanical Supplements (CRADAGAD), Hemp & CBD Product Wholesale Distribution (CRAOAIAG)

Keywords

• Pharmaceutical-grade CBD APIs
• CGMP cannabinoid manufacturing
• Hemp-derived active pharmaceutical ingredients
• White label CBD manufacturing
• Cannabinoid extraction and distillation

Headquarters

HQ city

Greeley

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. White Label Manufacturing: Provides white label production of finished CBD products (softgel capsules, tinctures) for brands seeking to launch products without establishing their own manufacturing infrastructure.
2. Contract Manufacturing (B2B Bulk Ingredients): Toll manufacturing and contract production of bulk CBD Distillate (100,000 kg/yr capacity) and CBD Isolate (50,000 kg/yr capacity) for pharmaceutical, nutraceutical, cosmetics, and food companies.
3. Finished Product Formulation: Formulation and manufacturing of finished CBD products including 50M+ softgel capsules and 1M tinctures per year under cGMP conditions.
4. Distribution Partnerships: Revenue derived through exclusive and non-exclusive distribution agreements with regional partners in Europe, Australia, and Brazil, selling pharmaceutical-grade CBD extracts under Vantage Hemp branding.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Core offering

Vantage Hemp manufactures pharmaceutical-grade hemp-derived cannabinoid active pharmaceutical ingredients (CBD Isolate, EP cGMP CBD Isolate, T-Free CBD Distillate, and CBG Isolate) and provides contract and white label manufacturing of finished CBD products (softgel capsules, tinctures, topicals, gummies). Output is sold to pharmaceutical, nutraceutical, cosmetics, and food companies requiring cGMP-, PIC/S-, ICH Q7-, WHO GMP-, FDA 21 CFR 210/211-, and EP cGMP-compliant ingredients with regulatory documentation for drug formulation, clinical trials, and commercial distribution.

Product overview

Vantage Hemp is a pharmaceutical-grade cannabinoid manufacturer offering a portfolio of CBD and CBG Active Pharmaceutical Ingredients (APIs) including Pharmaceutical Grade CBD Isolate (DMF), EP cGMP CBD Isolate (Ph. Eur.), T-Free CBD Distillate (PIC/S), and Pharmaceutical Grade CBG Isolate. The core products are APIs sold to pharmaceutical companies for drug formulation, clinical trials, and commercial pharmaceutical applications. Complementing the API portfolio, the company provides contract manufacturing and white label services for finished goods including tinctures, softgels, topicals, and gummies, along with R&D/formulation development and clinical trial program support. The two facilities (Falcon and Raven) provide 62,000 sq ft of cGMP certified hemp processing with extraction, winterization, distillation, and crystallization capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Grade CBD Isolate (DMF) CBD isolate with FDA Drug Master File registration (#037784), meeting pharmaceutical-grade specifications for active pharmaceutical ingredient use in clinical trials and drug development. Sold to pharmaceutical companies.
• EP cGMP CBD Isolate (Ph. Eur.) European Pharmacopoeia compliant CBD isolate meeting monograph 07/2024:3151 specifications, certified under EU cGMP standards for pharmaceutical use in European markets.
• T-Free CBD Distillate (PIC/S)

Quantifiable outcome

• 100,000 kg per year CBD Distillate extraction capacity
• +3 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and minor.

• WELDING GmbH & Co. KGcoreChannel Partner/ Reseller/ DistributorEuropean distribution partnership enabling Vantage Hemp to expand sales across Europe, India, and North Macedonia. WELDING serves as the exclusive distribution partner for these regions, handling local sales, regulatory navigation, and customer relationships for pharmaceutical-grade CBD ingredients and finished products.
• Medcan AustraliacoreChannel Partner/ Reseller/ DistributorExclusive distribution partnership for pharmaceutical-grade CBD extracts in Australia. Medcan Australia brings expertise in the Australian therapeutic goods regulatory framework and TGA compliance, while leveraging Vantage Hemp's GMP-certified manufacturing capabilities to serve the Australian pharmaceutical and nutraceutical markets.
• Brazilian PartnercoreChannel Partner/ Reseller/ DistributorPartnership with a Brazilian entity for the purpose of obtaining CBPF (Certificado de Boas Práticas de Fabricação) certification and ANVISA market validation for pharmaceutical-grade CBD extracts in Brazil. The partner operates under an asset-light model, enabling Vantage Hemp to enter the Brazilian market without direct capital investment while navigating local regulatory requirements.
• EIHA Novel Food ConsortiumminorOthersMembership in the European Industrial Hemp Association (EIHA) Novel Food Consortium, a collaborative industry body working to secure Novel Food approval for hemp-derived CBD products in the European Union. Vantage Hemp's participation supports regulatory advocacy and market development efforts in Europe.

Scale indicators6 records

Recent moves11 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/vantagehemp
• Facebookfacebook.com/vantagehemp

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vantage Hemp